Literature DB >> 20179923

Utility of positron emission tomography for tumour surveillance in children with neurofibromatosis type 1.

Mahendranath Moharir1, Kevin London, Robert Howman-Giles, Kathryn North.   

Abstract

PURPOSE: There is little consensus regarding optimal surveillance of optic pathway glioma (OPG) and plexiform neurofibroma (PNF) in childhood neurofibromatosis type 1 (NF1). (18)F-2-Fluoro-2-deoxy-D: -glucose (FDG) positron emission tomography and computed tomography (PET/CT) is employed in the surveillance of adult PNFs; but its utility has neither been specifically studied in children with PNFs nor in children with OPG.
METHODS: Review of PET/CT studies was performed in NF1 children with OPG or PNF. FDG-avidity of tumours was semi-quantitatively analysed and graded by calculating the maximum standardised uptake value (SUV(max)) [grade 1: <3 (low), grade 2: >3-<4 (intermediate), grade 3: >4 (intense)].
RESULTS: Eighteen children (ten girls; median age: 8.5-years) had PET/CT. Nineteen OPGs were imaged. The SUV(max) could be measured in 16. Ten were grade 1 and three each were grade 2 and grade 3. FDG-avidity reduced from grade 3 to grade 1 in two symptomatic OPGs following chemotherapy and this was associated with clinical improvement. PET/CT diagnosed symptomatic OPGs with a sensitivity of 0.625 [95% confidence interval (CI): 0.259-0.897] and specificity of 0.875 (95% CI: 0.466-0.993). Sixteen PNFs were imaged. Twelve were grade 1 and two each were grade 2 and grade 3. The two grade 3 PNFs were confirmed malignant peripheral nerve sheath tumours. PET/CT diagnosed malignant transformation with a sensitivity of 1.0 (95% CI: 0.197-1.0) and specificity of 0.857 (95% CI: 0.561-0.974).
CONCLUSION: PET/CT may contribute useful information to the surveillance of OPG in childhood NF1-particularly to identify progressive, symptomatic tumours. As in adults, PET/CT is useful for the detection of malignant transformation in PNFs in children with NF1.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20179923     DOI: 10.1007/s00259-010-1386-4

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  20 in total

Review 1.  Positron emission tomography and the central nervous system.

Authors:  R O Robinson; C D Ferrie; M Capra; M N Maisey
Journal:  Arch Dis Child       Date:  1999-09       Impact factor: 3.791

2.  The role of surgical biopsy in the diagnosis of glioma in individuals with neurofibromatosis-1.

Authors:  J R Leonard; A Perry; J B Rubin; A A King; M R Chicoine; D H Gutmann
Journal:  Neurology       Date:  2006-10-24       Impact factor: 9.910

3.  Surgical decision for adult optic glioma based on [18F]fluorodeoxyglucose positron emission tomography study.

Authors:  Junichi Miyamoto; Hiroyasu Sasajima; Kei Owada; Katsuyoshi Mineura
Journal:  Neurol Med Chir (Tokyo)       Date:  2006-10       Impact factor: 1.742

Review 4.  National Institutes of Health Consensus Development Conference Statement: neurofibromatosis. Bethesda, Md., USA, July 13-15, 1987.

Authors: 
Journal:  Neurofibromatosis       Date:  1988

5.  Von Recklinghausen neurofibromatosis. A clinical and population study in south-east Wales.

Authors:  S M Huson; P S Harper; D A Compston
Journal:  Brain       Date:  1988-12       Impact factor: 13.501

6.  Positron emission tomography in children with neurofibromatosis-1.

Authors:  A M Kaplan; K Chen; M A Lawson; D L Wodrich; C T Bonstelle; E M Reiman
Journal:  J Child Neurol       Date:  1997-11       Impact factor: 1.987

7.  Loss of neurofibromin is associated with activation of RAS/MAPK and PI3-K/AKT signaling in a neurofibromatosis 1 astrocytoma.

Authors:  N Lau; M M Feldkamp; L Roncari; A H Loehr; P Shannon; D H Gutmann; A Guha
Journal:  J Neuropathol Exp Neurol       Date:  2000-09       Impact factor: 3.685

Review 8.  Late-onset optic pathway tumors in children with neurofibromatosis 1.

Authors:  R Listernick; R E Ferner; L Piersall; S Sharif; D H Gutmann; J Charrow
Journal:  Neurology       Date:  2004-11-23       Impact factor: 9.910

Review 9.  The WHO classification of tumors of the nervous system.

Authors:  Paul Kleihues; David N Louis; Bernd W Scheithauer; Lucy B Rorke; Guido Reifenberger; Peter C Burger; Webster K Cavenee
Journal:  J Neuropathol Exp Neurol       Date:  2002-03       Impact factor: 3.685

10.  [18F]2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) as a diagnostic tool for neurofibromatosis 1 (NF1) associated malignant peripheral nerve sheath tumours (MPNSTs): a long-term clinical study.

Authors:  R E Ferner; J F Golding; M Smith; E Calonje; W Jan; V Sanjayanathan; M O'Doherty
Journal:  Ann Oncol       Date:  2007-10-11       Impact factor: 32.976

View more
  18 in total

1.  [18F]-Fluorodeoxyglucose positron emission tomography in children with neurofibromatosis type 1 and plexiform neurofibromas: correlation with malignant transformation.

Authors:  L L Tsai; L Drubach; F Fahey; M Irons; S Voss; N J Ullrich
Journal:  J Neurooncol       Date:  2012-03-11       Impact factor: 4.130

2.  Radiomic biomarkers informative of cancerous transformation in neurofibromatosis-1 plexiform tumors.

Authors:  J Uthoff; F A De Stefano; K Panzer; B W Darbro; T S Sato; R Khanna; D E Quelle; D K Meyerholz; J Weimer; J C Sieren
Journal:  J Neuroradiol       Date:  2018-06-27       Impact factor: 3.447

3.  Fractional anisotropy of the optic radiations is associated with visual acuity loss in optic pathway gliomas of neurofibromatosis type 1.

Authors:  Peter Matthew Kennedy de Blank; Jeffrey Ira Berman; Grant T Liu; Timothy Paul Leslie Roberts; Michael Jay Fisher
Journal:  Neuro Oncol       Date:  2013-05-07       Impact factor: 12.300

4.  fdg-pet in two cases of neurofibromatosis type 1 and atypical malignancies.

Authors:  P de Blank; K Cole; L Kersun; A Green; J J Wilkes; J Belasco; R Bagatell; L C Bailey; M J Fisher
Journal:  Curr Oncol       Date:  2014-04       Impact factor: 3.677

5.  Usefulness of (18)F-FDG-PET/CT in Evaluating a Brainstem Glioma in an Adult Patient with Neurofibromatosis Type 1.

Authors:  Giorgio Treglia; Barbara Muoio; Annemilia Del Ciello; Francesco Bertagna
Journal:  Nucl Med Mol Imaging       Date:  2013-02-07

6.  Therapeutics for childhood neurofibromatosis type 1 and type 2.

Authors:  Simone L Ardern-Holmes; Kathryn N North
Journal:  Curr Treat Options Neurol       Date:  2011-12       Impact factor: 3.598

7.  68Ga-NOTA-Aca-BBN(7-14) PET imaging of GRPR in children with optic pathway glioma.

Authors:  Jingjing Zhang; Yongji Tian; Deling Li; Gang Niu; Lixin Lang; Fang Li; Yuhan Liu; Zhaohui Zhu; Xiaoyuan Chen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-07-03       Impact factor: 9.236

8.  Usefulness of whole-body fluorine-18-fluorodeoxyglucose positron emission tomography in patients with neurofibromatosis type 1: a systematic review.

Authors:  Giorgio Treglia; Silvia Taralli; Francesco Bertagna; Marco Salsano; Barbara Muoio; Pierluigi Novellis; Maria Letizia Vita; Fabio Maggi; Alessandro Giordano
Journal:  Radiol Res Pract       Date:  2012-09-09

Review 9.  The Role of PET in Supratentorial and Infratentorial Pediatric Brain Tumors.

Authors:  Angelina Cistaro; Domenico Albano; Pierpaolo Alongi; Riccardo Laudicella; Daniele Antonio Pizzuto; Giuseppe Formica; Cinzia Romagnolo; Federica Stracuzzi; Viviana Frantellizzi; Arnoldo Piccardo; Natale Quartuccio
Journal:  Curr Oncol       Date:  2021-07-05       Impact factor: 3.677

10.  The Use of Magnetic Resonance Imaging Screening for Optic Pathway Gliomas in Children with Neurofibromatosis Type 1.

Authors:  Carlos E Prada; Robert B Hufnagel; Trent R Hummel; Anne M Lovell; Robert J Hopkin; Howard M Saal; Elizabeth K Schorry
Journal:  J Pediatr       Date:  2015-07-29       Impact factor: 6.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.